How has Kura Oncology's deferred revenue, net of current portion changed year-over-year?

Kura Oncology's deferred revenue, net of current portion increased by 53.3% year-over-year, from $271.93M to $416.75M.

Kura Oncology KURA Deferred revenue, net of current portion

Deferred revenue, net of current portion at other companies

ExelixisEXEL

——

Arcus BiosciencesRCUS

——

Segments

By product

See full

Commercialization Services$273.7M—

Other financials

Income statement

See full

Revenue$18.3M+29.5%

Gross profit$18.0M—

Operating income-$78.8M-21.8%

Net income-$73.3M-27.7%

EPS (diluted)-$0.83-25.8%

Balance sheet

See full

Cash & equivalents$39.1M-23.8%

Total debt$24.3M+25.4%

Total equity$107.9M-70.4%

Total assets$652.6M-12.3%

Cash flow

See full

Operating cash flow-$85.9M-19.4%

CapEx$128.0K-56.2%

Free cash flow-$86.0M-19.1%

Valuation

See full

Market cap$919.7M+81.6%

Enterprise value$904.89M+90.7%

P/S12.8×+3.5×

Profitability

See full

Operating margin-443.5%+103pp

Net margin-411.2%+125pp

FCF margin130.6%+74.1pp

Returns & leverage

See full

Return on equity-124.7%-252pp

Debt / equity0.2×+0.2×

Current ratio6.1×-1.9×

Where this comes from

Reported directly by Kura Oncology in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Kura Oncology’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kura Oncology's deferred revenue, net of current portion.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Kura Oncology's deferred revenue, net of current portion?: Kura Oncology (KURA) reported deferred revenue, net of current portion of $416.75M in Q1 2026.
How has Kura Oncology's deferred revenue, net of current portion changed year-over-year?: Kura Oncology's deferred revenue, net of current portion increased by 53.3% year-over-year, from $271.93M to $416.75M.